Outrageous Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 106.13%
- Profit Growth -34.49%
- Ebitda 191.04%
- Net Worth -2.44%
- Total Assets 44.70%
About Outrageous Pharmaceuticals
Outrageous Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 April 2016 (Eight years and nine months 11 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Alaka Patil, Komal Shinde, and Priyanka Parmaj serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299PN2016PTC164063
-
Company No.
164063
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Apr 2016
-
Date of AGM
09 Jan 2024
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Outrageous Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alaka Patil
|
Director | 22-Apr-2016 | Current |
|
Komal Shinde
|
Director | 22-Apr-2016 | Current |
|
Priyanka Parmaj
|
Director | 22-Apr-2016 | Current |
Financial Performance of Outrageous Pharmaceuticals.
Outrageous Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 106.13% increase. The company also saw a substantial fall in profitability, with a 34.49% decrease in profit. The company's net worth dipped by a decrease of 2.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Outrageous Pharmaceuticals?
Unlock access to Outrageous Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Outrageous Pharmaceuticals?
Unlock and access historical data on people associated with Outrageous Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Outrageous Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Outrageous Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
